Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/18/2025

Pancreatitis Risk with Januvia (Sitagliptin)

Introduction to Pancreatitis Risk

  • The American Diabetes Association recommends discontinuing Januvia if pancreatitis is suspected and not restarting in patients with a history of pancreatitis, due to the potential concern of pancreatitis with DPP-4 inhibitors like sitagliptin (Januvia) 1

Patient Screening and Monitoring

  • Before initiating Januvia, screen for history of pancreatitis and assess for other risk factors for pancreatitis, and do not initiate in patients with a history of pancreatitis, as recommended by the American Diabetes Association 1
  • Patients with severe hypertriglyceridemia (>500 mg/dL) are at increased risk for pancreatitis, and extra caution should be used when considering Januvia in these patients 2

Treatment and Discontinuation

  • If pancreatitis is suspected during treatment with Januvia, discontinue Januvia immediately, perform appropriate diagnostic tests, and provide supportive care as needed, as recommended by the American Diabetes Association 1
  • If pancreatitis occurs, permanently discontinue Januvia and consider alternative diabetes medications with lower or no pancreatitis risk 1

Risk Assessment

  • The absolute risk of pancreatitis with sitagliptin appears to be low (approximately 0.1-0.3% in clinical studies), but potentially serious when it occurs, according to the American Diabetes Association's 2025 Standards of Care 1

REFERENCES

2

Management of Hypertriglyceridemia [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025